Australia Vaccine Contract Manufacturing Market Size & Outlook
Related Markets
Australia vaccine contract manufacturing market highlights
- The Australia vaccine contract manufacturing market generated a revenue of USD 111.3 million in 2024 and is expected to reach USD 160.7 million by 2030.
- The Australia market is expected to grow at a CAGR of 6.3% from 2025 to 2030.
- In terms of segment, attenuated vaccine was the largest revenue generating vaccine type in 2024.
- DNA Vaccines is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Vaccine contract manufacturing market data book summary
| Market revenue in 2024 | USD 111.3 million |
| Market revenue in 2030 | USD 160.7 million |
| Growth rate | 6.3% (CAGR from 2025 to 2030) |
| Largest segment | Attenuated vaccine |
| Fastest growing segment | DNA Vaccines |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Subunit Vaccines, Attenuated Vaccine, Inactivated Vaccine, Toxoid Vaccines, DNA Vaccines |
| Key market players worldwide | Lonza Group Ltd, FUJIFILM Holdings Corp, Merck KGaA, Catalent Inc, Icon PLC, Syngene, Curia, Ajinomoto Co Inc, IDT Biologika |
Other key industry trends
- In terms of revenue, Australia accounted for 2.4% of the global vaccine contract manufacturing market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, India vaccine contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 598.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Contract Manufacturing Market Scope
Vaccine Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| IDT Biologika | View profile | 1001-5000 | Dessau, Sachsen-Anhalt, Germany, Europe | https://idt-biologika.de/ |
| Syngene | View profile | 1001-5000 | Bangalore, Karnataka, India, Asia | http://www.syngeneintl.com |
| Curia | View profile | 1001-5000 | Albany, New York, United States, North America | https://curiaglobal.com |
| Ajinomoto Co Inc | View profile | 43318 | 15-1, Kyobashi 1-chome, Chuo-ku, Tokyo, Japan, 104-8315 | http://www.ajinomoto.co.jp |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
Australia vaccine contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.
Attenuated vaccine was the largest segment with a revenue share of 30.37% in 2024. Horizon Databook has segmented the Australia vaccine contract manufacturing market based on subunit vaccines, attenuated vaccine, inactivated vaccine, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Australia has one of the best healthcare systems in the world. The increasing awareness about the need for early detection of lifestyle and chronic diseases is expected to boost the market in the country. Similar to governments of developed economies, the Australian government undertakes schemes to provide medicines at subsidized rates.
For instance, as per the Pharmaceutical Benefits Scheme (PBS), medicines are available for all eligible patients at a subsidized cost. These factors are expected to improve & promote the demand for pharmaceutical manufacturing, thus boosting the demand for vaccine contract manufacturing services in the country.
Adopting advanced manufacturing technologies and processes can enhance efficiency, reduce costs, & improve the overall quality of oral solid dosage manufacturing. This is expected to support the demand for vaccine manufacturing in Australia and create opportunities for CMOs.
Reasons to subscribe to Australia vaccine contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia vaccine contract manufacturing market databook
-
Our clientele includes a mix of vaccine contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia vaccine contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Australia vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia vaccine contract manufacturing market size, by vaccine type, 2018-2030 (US$M)
Australia Vaccine Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
